Moody’s upgrades Teva to investment grade, citing growth and continued debt reduction
Ratings agency raises Israeli drugmaker to Baa3 with a stable outlook, pointing to stronger earnings, improving margins, solid cash flow and expectations that debt will continue to fall over the next 12 to 18 months